Sánchez-Peña, LucíaRodríguez-Pallares, SaludBlanco Martín, TaniaPérez-Rodríguez, GloriaAja-Macaya, PabloGonzález-Pinto, LucíaLópez-Hernández, InmaculadaAracil, BelénBeceiro Casas, AlejandroBou, GermánArca-Suárez, Jorge2026-08-202026-08-202026-05-29Sánchez-Peña L, Rodríguez-Pallares S, Blanco-Martín T, Pérez-Rodríguez G, Aja-Macaya P, González-Pinto L, López-Hernández I, Aracil García B, Beceiro A, Bou G, Arca-Suárez J. Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales. Antimicrob Agents Chemother. 2026 Jul;70(7):e0019526.1098-6596https://hdl.handle.net/2183/49057Comparative study[Abstract] We evaluated the activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against isogenic Escherichia coli and clinical Enterobacterales isolates producing broad-spectrum β-lactamases. Avibactam and ledaborbactam enhanced ceftibuten activity against transformants producing serine-β-lactamases. Ceftibuten/xeruborbactam was also active against VIM and some IMP producers. All combinations were active against OXA-48- and KPC-producing clinical isolates. Ceftibuten/xeruborbactam also retained activity against VIM-producing clinical strains. Susceptibility rates for MBL producers varied, depending on the CLSI or EUCAST breakpoints applied.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/EnterobacteralesAvibactamCarbapenemaseCarbapenemase-producing EnterobacteralesCeftibutenLedaborbactamXeruborbactamβ-lactamβ-lactamaseβ-lactamase inhibitorjournal articleopen access10.1128/AAC.00195-26